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Abstract
Background: Cardiovascular disease is the chief cause of death in Taiwan and many countries, of which
myocardial infarction (MI) is the most serious condition. Hyperlipidemia appears to be a significant cause of
myocardial infarction, because it causes atherosclerosis directly. In recent years, copy number variation (CNV) has
been analyzed in genomewide association studies of complex diseases. In this study, CNV was analyzed in blood
samples and SNP arrays from 31 myocardial infarction patients with hyperlipidemia.
Results: We identified seven CNV regions that were associated significantly with hyperlipidemia and myocardial
infarction in our patients through multistage analysis (P<0.001), at 1p21.3, 1q31.2 (CDC73), 1q42.2 (DISC1), 3p21.31
(CDCP1), 10q11.21 (RET) 12p12.3 (PIK3C2G) and 16q23.3 (CDH13), respectively. In particular, the CNV region at
10q11.21 was examined by quantitative real-time PCR, the results of which were consistent with microarray
findings.
Conclusions: Our preliminary results constitute an alternative method of evaluating the relationship between CNV
regions and cardiovascular disease. These susceptibility CNV regions may be used as biomarkers for early-stage
diagnosis of hyperlipidemia and myocardial infarction, rendering them valuable for further research and discussion.
Background
Cardiovascular disease is the principal cause of death in
Taiwan and many countries, of which myocardial infarc-
tion (MI) is the most serious condition. Low-density
lipoprotein (LDL) cholesterol, high-density lipoprotein
(HDL) cholesterol, and triglyceride (TG) levels in the
blood are risk factors for cardiovascular disease. Elevated
concentrations of total cholesterol (TC) and LDL in
serum are associated with an increased risk of coronary
heart disease [1]. Hyperlipidemia is a significant cause of
MI, because it is characterized by high serum TC, LDL,
and TGs and because its complex mechanisms affect
progressive atherosclerosis [2].
In the past decade, genome-wide association studies
(GWASs) on hyperlipidemia and myocardial infarction
have examined gene expression and heredity in families
and identified several candidate genes and SNPs.
GWASs have linked SNPs to susceptibility to cardiovas-
cular diseases, such as familial combined hyperlipidemia
(FCHL) [3] and dyslipoproteinemia [4]. Many GWASs
of cardiovascular disease have identified several loci; for
example, the WTCCC study reported nine loci that
were robustly associated with coronary artery disease,
including 9p3l and 9p34 [5]. These loci were also dis-
covered in South Korean [6] and Italian populations [7].
These results indicate that gene variation mediates
FCHL and hyperlipidemia.
Of the sequence variations in the human genome,
copy number variation (CNV) contributes directly to
changes in gene expression through gene dosage effects.
CNV is a variation in the DNA sequence and can affect
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the expression of nearby and distal genes, causing phe-
notypic differences. Stranger et al. analyzed the associa-
tion of expression levels of 14,925 transcripts with SNPs
and CNVs, noting that signals from these types of varia-
tion have little overlap [8]. Examining the genome for
both variants might be an effective means of determin-
ing the causes of complex phenotypes and diseases in
humans.
CNV regions have been estimated to cover 18% of
the human genome [9]. Inherited CNVs underlie men-
delian diseases, and some copy number (CN) variable
genes are associated with human diseases, such as
schizophrenia and autism [10,11]. Lanktree and Hegele
suggest that rare and common CNVs contribute to the
susceptibility to metabolic disease. A common CNV in
LPA, encoding apolipoprotein(a), is the primary deter-
minant of plasma lipoprotein(a) concentrations and a
risk factor for atherosclerosis, and CNVs in LDLR
mediate heterozygous familial hypercholesterolemia in
patients [12]. CNVs are a significant source of genetic
diversity, but their influence on phenotypic variability,
including disease susceptibility, remains poorly under-
stood. Their findings have encouraged further investi-
gation of the relationship between CNVs and
cardiovascular disease.
With regard to cardiovascular disease, several articles
on copy number variation in hyperlipidemia patients or
copy number variation in myocardial infarction patients
have been reported, but there is no CNV research inte-
grating both diseases. In this study, we try to discover
novel suspect CNV region from myocardial infarction
patients with hyperlipidemia. Study of disease specific
CNV region of myocardial infarction patients with
hyperlipidemia might help to find out the disease
mechanism and might aid in disease prediction.
Results
Analysis of CNV regions
A total of seven loci disrupted by CNVs were found.
These included five gains and two losses regions, and
these were associated significantly with hyperlipidemia
and myocardial infarction (P≤0.001). The shortest CNV
range is 1935 bp, and the longest CNV range is 9811 bp.
The average of CNV range we observed is 5260 bp. A
summary for each CNV region is presented in Table 1.
The gain CNV region on 1p21.3 (ch1: 95164205) lay
near the start of solute carrier family 44, member 3
(SLC44A3). This CNV region was detected in 10
patients of case group, and the average CN of this
region is 3.06 (P=4.13×10-3). In NCBI dbSNP build 131,
there were 79 SNPs lie in this region and 23 SNPs in
these were reported by HapMap. The CN of each
patients and average CN of this region were presented
in figure 1a, and SNP array profile of this CNV region is
presented in figure 1b.
The loss CNV region on 1q31.2 (ch1: 193213064) lay
in the coding region of cell division cycle 73, Paf1/RNA
polymerase II complex component (CDC73). This CNV
region was detected in 13 patients of case group, and
the average CN of this region is 0.76 (P=2.29×10-4,
Figure 2a and 2b). In NCBI dbSNP build 131, there
were 28 SNPs lie in this region, but only rs7525286 and
rs12117100 in these SNPs were reported by HapMap.
We have not discovered any related literature to
descript their role in hyperlipidemia or cardiovascular
disease of these two SNPs.
The gain CNV region on 1q42 (ch1: 232154677) lay in
disrupted in schizophrenia 1 (DISC1). This CNV region
was detected in 15 patients of case group, and the aver-
age CN of this region is 3.40 (P=3.5×10-5). DISC1
encodes a protein with multiple coiled coil motifs that
resides in the nucleus, cytoplasm, and mitochondria and
regulates neurite outgrowth and cortical development
through its interaction with other proteins. In NCBI
dbSNP build 131, there were 109 SNPs lie in this region
and 21 SNPs in these were reported by HapMap.
The loss CNV region on 3p21.31 (ch3: 45217649) lay
in CUB domain containing protein 1 (CDCP1), which
encodes a transmembrane protein that contains 3 extra-
cellular CUB domains is expressed on the cell surface.
This CNV region was detected in 21 patients of case
group, and average CN of this region is 1.22 (P<1×10-6).
In NCBI dbSNP build 131, there were 74 SNPs lie in
this region, 11 SNPs in these were reported by HapMap.
The gain CNV region on 10q11 (ch10: 43623002) lay
in the coding region of protein P07949 (Swiss-Prot:
Table 1 Significant CNV regions
Cytoband Start position of CNV region (bp) Type Total aberrations Avg. CN Length (bps) Gene
1p21.3 95164205 Gain 10 3.057 6757
1q31.2 193213064 Loss 13 0.76 4631 CDC73
1q42.2 232154677 Gain 15 3.4 9552 DISC1
3p21.31 45217649 Loss 21 1.217 3985 CDCP1
10q11.21 43623658 Gain 19 3.142 1935 RET
12p12.3 18574942 Gain 11 3.155 4461 PIK3C2G
16q23.3 82706957 Gain 12 3.161 5706 CDH13
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P07949.3) in ret proto-oncogene (RET). RET is a mem-
ber of the cadherin superfamily and encodes a receptor
tyrosine kinase. This CNV region was detected in 19
patients of case group, and the average CN of this
region is 3.14 (P=4×10-6, Figure 3a and 3b). There were
six SNPs in this region that were reported by dbSNP
build 132 and three SNPs in these (rs17028, re2742240,
rs2435355) were reported by HapMap. We have not dis-
covered any related literature to descript their role in
hyperlipidemia or cardiovascular disease of these three
SNPs unfortunately.
The gain CNV region in 12p12.3 (ch12: 18574942) lay
in phosphoinositide-3-kinase, class 2, gamma polypep-
tide (PIK3C2G), which encodes a protein in the phos-
phoinositide 3-kinase (PI3K) family. PIK3C2G contains
a lipid kinase domain and a C-terminal C2 domain,
characteristic of class II PI3-kinases, and function of
PIK3C2G has not yet been determined. This CNV
region was detected in 11 patients of case group, and
the average CN of this region is 3.15 (P=1.67×10-4).
There were 42 SNPs lie in this region that NCBI dbSNP
build 132 and 10 SNPs in these were reported by
HapMap.
The gain CNV region in 16q23.3 (ch16: 82706957) lay
in cadherin 13, H-cadherin, heart (CDH13). Like RET,
CDH13 is a member of the cadherin superfamily, and it
is a putative mediator of cell-cell interactions in the
heart and negatively regulates neural cell growth. This
CNV region was detected in 12 patients of case group,
and the average CN of this region is 3.15 (P=5.51×10-4).
There were 101 SNPs lie in this region that NCBI
dbSNP build 132 and 20 SNPs in these were reported
by HapMap.
Verification of CNV region by real-time PCR
Figure 4 shows the real-time PCR results of the gain
CNV region on 10q11.21 (ch10: 43623002). In 19 sam-
ples from case group which detected to have this gain
CNV region, the average CN is 3.14235. Contrast the 9
samples from control group, the average CN is only
1.97 and shows the copy number of this region is
unchanged. It confirms the real-time PCR experiment
result is same to microarray.
Discussion
CNVs have been implicated in few mendelian diseases
on the molecular level. It would be premature to predict
the relative proportion of complex diseases that are
attributed to SNPs and CNVs due to the limited knowl-
edge on the genetic basis of common, complex pheno-
types [13]. In this study, hyperlipidemia and myocardial
infarction-specific CNV regions were identified by CNV
analysis on a SNP array, and some of which lay in
regions that have been linked to hyperlipidemia and
myocardial infarction in GWASs (Table 2). Yip et al.
have linked atherogenic dyslipidemia and chromosome
1q31 [14]; Shmulewitz et al. [15] also observed that
1p31 and other regions are associated with significant
heritability of metabolic traits. These regions coincide
with our findings, and our CNV analysis narrows the
range of functional gene regions.
In the present study, we have two interesting observa-
tions to bring out the possibility of relationship between
the specific CNV region and hyperlipidemia in relative
small p-value. The first observation is that the gain
Figure 1 The CN state and SNP array profile graph of gain CNV
region on lp21.3. (a) The distribution of CNs in the gain CNV region
on 1p21.3. Blue and red dots indicate male and female patients,
respectively; (b) SNP array profile for part of 1p21.3; the black box
marks the location of the gain CNV region.
Figure 2 The CN state and SNP array profile graph of loss CNV
region on 1q31.2. (a) The distribution of CNs in the loss CNV region
on 1q31.2. Blue and red dots indicate male and female patients,
respectively; (b) SNP array profile for part of 1q31.2; the black box
marks the location of this CNV region.
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CNV region lies within the coding region of P07949 of
RET (ch10: 43623002), and it is a member of the cad-
herin superfamily and encodes a receptor tyrosine kinase
(Figure 3c). Chia implicated adhesion molecules in
atherogenesis in a report on the relationship between
cell surface proteins and hyperlipidemia and focusing on
interactions between the endothelium, monocytes, and
leukocytes and the influence of cytokines, oxidized low-
density lipoproteins, and genetic determinants [16]. The
second observation is that the gain CNV region on
16q23.3 (ch16: 82706957) lay in CDH13. Dong et al.
noted the significant linkage between TC level and
Figure 3 The CN state and SNP array profile graph of gain CNV region on 10q 11.21. (a) The distribution of CNs in the gain CNV region on
10q11.21. Blue and red dots indicate male and female patients, respectively; (b) SNP array profile for 10q11.21; the black box shows the location
of this CNV region; (c) Characteristics and exon region of this gain CNV region in protein P07949.
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specific expression on 16q23 (LOD=3.35) in a genome-
wide linkage scan of 1211 subjects from 100 Dominican
families for 5 quantitative lipid traits, which identified
several nearby genes, including CDH13[17]. The gene
function of RET and CDH13 is similar and belong to
cell-surface protein, and several literatures bring out the
function of these two genes may influence the level of
low-density lipoproteins.
To further support our result, we have checked the
haplotype data from our patient cohort. First, there are
four haplotypes in represented CNV region of RET by
query HapMap (rs7922745, rs10899917, rs17463850,
rs1537796) and these four SNPs are not listed in the
patient’s haplotype data. These four SNPs are located in
the same block. Second, there is only a SNP rs8045610
in represented CNV region of CDH13 by query Hap-
Map, and this SNP is also not listed in the patient’s
haplotype data. Although there is no direct evidence
indicating a relation between hyperlipidemia and these
two CNV regions, these regions were still valuable to
investigate the role of regulation in related gene.
Comparative genomic hybridization (CGH) and single-
nucleotide polymorphism (SNP) arrays are high-resolu-
tion tools that can be used to detect subtle CN altera-
tions on the genomic scale. SNP arrays cost less and are
easier to use than CGH in detecting one SNP and it can
detect all SNPs in the entire genome, allele frequencies,
and copy numbers in a single reaction. HMM segmenta-
tion and genomic segmentation are the principal algo-
rithms in CNV detection and help us to discover the
CNV in patients; however, multi-base and multi allele
SNPs cannot be detected by SNP arrays and increase
false negative and false positive. Additional experiment
platforms such as fluorescence in situ hybridization
(FISH), CGH array or real-time PCR will be needed to
obtain more reliable results [13]. Fortunately, the real-
time PCR result of observed CNV in 10q11.21 is same
to microarray and in preliminary confirms our result.
As the sample size is small (n=31), we use the two-
tailed Fisher’s exact test and only consider events with
high significance (P<0.001). Besides, these 31 patients
are independent individuals; none of any two patients
come from the same family. However, our findings may
needs to be viewed with caution and be verified to step
forward.
CNVs vary slightly in location and frequency between
populations. The distribution of CNVs differs, based on
genetic background, and population-specific CNVs can
result in the divergence of physiological characteristics
and disease prevalence between races [18]. Previous
CNV discoveries were mostly limited to the sample
from HapMap and to samples from Caucasian indivi-
duals, and other CNV survey studies using different eth-
nic backgrounds were needed. Therefore, all subjects in
our study were Taiwanese and only Han Chinese and
Japanese population data in HapMap project were con-
sidered for the help of CNV analysis.
Metabolic disorders were considered as correlated
with multiple gene variation [19]. In this study, we dis-
covered several CNV regions in patients and propose
that might regulate gene expression and subsequent
synthesis of specific proteins in hyperlipidemia, and we
will make every effort to discover stronger evidences in
the relationship between hyperlipidemia and specific
CNVs in future.
Conclusions
CNV is an important mechanism of hyperlipidaemia,
and performing CNV analysis in hyperlipidemia and MI
patients through bioinformatics methods is helpful in
identifying disease-specific variants of genes. In this
Figure 4 Real-time PCR result of the CNV region on 10q11.21 in
RET. The CN state of case samples (n = 19, blue bar) are higher
than the CN state of control samples (n = 9, green bar).
Table 2 Description and related literature of identified
CVNRs




1q31.2 193213064 CDC73 Yip et al. [14]
Shmulewitz et al. [15]
1q42.2 232154677 DISC1 Brouwers et al. [29]
3p21.31 45217649 CDCP1
10q11.21 43623658 RET Kiechl et al.[30]
Samani et al.[5,31]
12p12.3 18574942, PIK3C2G Eijgelsheim et al.[32]
Johnson et al.[33]
16q23.3 82706957 CDH13 Ruixing et al.[34]
Avramoglu et al.[35]
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study, seven CNV regions that associated with hyperlipi-
demia and MI were discovered and real-time PCR was
performed to confirm the result. After verified the inde-
pendent of CNV and haplotype in patient cohort, these
susceptibility CNVs reported in this study might associ-
ate with myocardial infarction patients with hyperlipide-
mia and might have the potential to be biomarkers.
Methods
Study subjects
Forty blood samples were collected from nine healthy
Taiwanese controls and 31 Taiwanese patients from the
department of cardiovascular medicine in Changhua
Christian Hospital and Feng Chia University from
December 11, 2009 to March 24, 2011.
The inclusion and exclusion criteria for enrolling
patients were drawn from the Prospective Cardiovascu-
lar Munster study [20] and Framingham Heart Study
[21]. In brief, patients aged between 20 and 75 years
with coronary arterial disease with more than 50% ste-
nosis, as proven by cardiac catheterization, and a history
of hyperlipidemia with serum cholesterol level greater
than 240 mg/dL or low-density lipoprotein greater than
155 mg/dL were enrolled.
The criteria for the control group included normal
blood sugar concentration, normal blood cholesterol
and lipoprotein concentration, normal electrocardio-
gram, no history of angina, normal cardiovascular physi-
cal examination results, and a 10-year risk of having a
heart attack lower than 10% [22]. Participants with a
history of diabetes, stroke, heart failure, or other major
systemic diseases were excluded from the control group.
The clinical information of the CAD patients and
healthy controls are shown in Table 3.
Thirty one additional controls were selected randomly
from 82 Han Chinese and Japanese samples of the Inter-
national HapMap Project [23]. To minimize differences
in gene variants between races, only Han Chinese and
Japanese samples were selected for the control group to
compare with the Taiwanese samples.
The data discussed in this publication have been
deposited in NCBI’s Gene Expression Omnibus (GEO)
[24] and are accessible through GEO series accession
number GSE31276. Ethical permission for all partici-
pants was obtained from the institutional review board
of Changhua Christian Hospital, Taiwan.
DNA extraction and preparation for microarray
experiment
Genomic DNA was extracted from peripheral blood
buffy coat using the Qiagen PureGene Blood Kit (Qia-
gen Inc., Valencia, USA) per the manufacturer’s instruc-
tions. Before performing the microarray assay, the
quality of the DNA was examined on a NanoDrop spec-
trophotometer (Thermo, Wilmington, USA). For each
sample, 50 µg of genomic DNA was used to generate
targets per the Affymetrix Genome-Wide Human SNP
Array 6.0 protocol. Targets were prepared if 50 µg of
amplified DNA was available and if they were between
250 and 2000 bp and hybridized per the manufacturer’s
recommendation.
Detection of CNV
To identify all CNV regions that were linked to hyperlipi-
demia and myocardial infarction, multistage analysis was
performed for 31 controls and 31 patients. First, all
inbound SNP array data were imported after QC checked
(Call Rate > 97%, Contrast QC > 0.4, MAPD < 0.3), and
copy number profiles were created from allele intensities.
The threshold parameter of normalization, quality con-
trol and outlier treatment of imported SNP arrays are fol-
lowing the manufacturer’s instruction. Population data
from HapMap was used to generate the copy number
(CN) baseline. Next, CNV detection was performed. The
CN profile was analyzed using the genomic segmentation
algorithm of PARTEK Genomic Suite 6.5 (PARTEK Inc.,
St. Louis, USA). The criteria with detected CNV seg-
ments were as follows: (1) neighboring regions with sig-
nificantly different average intensities, and the significant
level we chose is p-value less than 0.001, (2) breakpoints
(region boundaries) that yielded the optimal statistical
significance (smallest p-value), and (3) detected regions
with at least 10 probes. Single nucleotide polymorphisms
with a smoothing value below and above 2±0.3 were con-
sidered a loss and gain, respectively.
Next, we group all CNV regions in each sample which
located in the same chromosome and have same start
and stop position, and we get four values and a 2x2
contingency table for each CNV region: (a) patients with
CNV, (b) controls with CNV, (c) patients without CNV,
and (d) controls without CNV. Considering the small
sample size, two-tailed Fisher’s exact test was performed
to obtain a p-value for each CNV region, and the
threshold of p-value we chose is 0.001.
Common CNV regions were excluded from these sig-
nificant CNV regions using the Database of Genomic
Table 3 Clinical characteristics of patients and healthy
controls
Variable Affected (mean±SE) Non-affected
(mean±SE)
N (subjects) 31 9
Age (years) 45.0±18.3 36.8±17.2
Gender (male/female) 21/10 5/4
Total cholesterol (mmol/L) 265.7±10.5 -
Triglycerides (mmol/L) 244.9±34.4 -
LDL cholesterol (mmol/L) 164.0±9.6 -
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Variants (DGV) to specify the CNV regions in patients
[25,26], NCBI RefSeq [27] and Geneious 5.4 [28] were
used to annotate the location and coding region of each
significant CNV region in the genome.
Verification CNV region by real-time PCR
Quantitative real-time polymerase chain reaction (PCR)
were performed using the TaqMan Copy Number Assay
(Life Technologies Co., California, USA) to verify the
CNV region on 10q11.21 (ch10: 43623658), the most
significant result that we obtained (P<1×10-5). Nineteen
patients and nine healthy controls were assayed for this
CNV region by using the pre-designed probe
Hs00975020_cn from the manufacturer. PCR was per-
formed in quadruplicate; each 10-µl reaction comprised
10 ng gDNA and 1 TaqMan probe/primer mix in 1
TaqMan Universal Master Mix, amplified on an Applied
Biosystems 7900HT SDS. The cycling conditions were
50°C for 2 min, 95°C for 10 min, and 40 cycles of 92°C
for 15 sec, 60°C for 1 min. Real-time data were collected
by the ABI SDS 2.3 software. ABI CopyCaller 1.0 soft-
ware was used for real-time PCR data analysis.
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